Historical AI Consensus

This page preserves the research and market snapshot packaged for this batch. It is not updated with later prices or revised advisor outputs.

Symbol: ARGX.BRU
Batch: 7
Published: September 20, 2026
AI Advisors: 14

Historical AI Consensus Investment Thesis

Argen-X (ARGX) Stock Forecast and AI Rating

Deep analysis published Sep 21 2026Original pricing snapshot Sep 18 2026

Publisher

Russlan Ramdowar

12 min read

Published 1-Year and 5-Year Forecast Outlook

Forecast targets and rating

Published batch rating

NEUTRAL

Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.

2027

1-Year

BUY

€977

+12.1%

2031

5-Year

NEUTRAL

€1,398

+60.4%

Published batch insight

Rare Disease Cash Flow Compounding Collides With Long Term Valuation Multiple Compression

High consensus confirms that subcutaneous autoantibody clearance drives substantial commercial operating leverage across chronic autoimmune indications. However, sharp divergence persists regarding whether robust earnings compounding can overcome valuation multiple compression caused by encroaching class competition, statutory payer rebate demands, and elevated long-term sovereign bond yields.

Deep Forecast Analysis by iPulse AI Engine

This analysis preserves the original published batch. Audit published forecasts in full transparency

Elon Musk (Visionary), Superintelligence (Anthropologist), Warren Buffett (Value Purist), Machiavelli (Insider), Universal Investor (Polymath), J.P. Morgan (Titan), Michael Burry (Vulture), Ray Dalio (Strategist), Sherlock Holmes (Whistleblower). Some archetypes run in multiple modes, resulting in 14 advisors total.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Full published thesis

Executive Summary

If you invested $10,000 in Argen-X at the forecast anchor (2026-09-18): $16,688 in five years versus $13,892 for S&P 500 benchmark.

Argen-X · Synthesized ConsensusS&P 500 benchmark

Figure: Five-year synthesized consensus value path for Argen-X compared with S&P 500 benchmark. The path uses the synthesizer’s normalized opinion weights.

20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView table

Frozen forecast from 18 Sept 2026. Prices in EUR; returns exclude dividends. Each quarter is compounded from the previous quarter.

Anchor: 871.4 EUR1-year price return: +12.09%5-year price return: +60.41%

Swipe the table horizontally to read every column.

Twenty quarterly synthesized price forecasts in EUR, with returns and rationale
Quarter	Target (EUR)	Quarter return	Total return	Forecast rationale
Q4 2026	897.54	+3.00%	+3.00%	Empasiprubart multifocal motor neuropathy data readout and initial subcutaneous CIDP adoption drive commercial optimism. Strong underlying volume growth is partially counterbalanced by acquisition cash digestion and elevated discount rates capping aggressive valuation multiples.
Q1 2027	928.60	+3.46%	+6.56%	Full-year 2026 audited financial reporting confirms expanding operating profitability and accelerating European commercial uptake. Reconciled earnings metrics demonstrate genuine operating leverage, though persistent sovereign bond yields prevent immediate valuation multiple expansion.
Q2 2027	949.68	+2.27%	+8.98%	Subcutaneous autoinjector rollout broadens outpatient access and reinforces patient adherence across core neurology indications. Commercial gains face minor friction from tariff pass-through uncertainties and seasonal reimbursement resets, keeping overall appreciation measured and orderly.
Q3 2027	976.74	+2.85%	+12.09%	International commercial expansion across Europe and Japan broadens recurring revenues, offsetting seasonal summer prescription slowdowns. Rising interest rate headwinds and cautious valuation discounting temper market enthusiasm, resulting in modest fundamental earnings-driven price progress.
Q4 2027	1,011.71	+3.58%	+16.10%	Late-stage clinical trial updates in rheumatology indications yield supportive efficacy markers, validating platform adjacency. Robust quarterly free cash flow generation reinforces balance-sheet resilience, attracting institutional capital into year-end portfolio positioning.
Q1 2028	1,033.16	+2.12%	+18.56%	Fiscal 2027 financial disclosures reveal operating margins consolidating above thirty percent. Sustained patient volume gains across established territories offset early payer rebate renegotiations, supporting steady multiple consolidation across major European exchanges.
Q2 2028	1,064.67	+3.05%	+22.18%	Regulatory approvals for adjacent neuromuscular indications broaden addressable commercial volume. Strong clinical switching barriers protect established core revenue streams, though advancing competitive pipeline disclosures from rival pharmaceutical developers introduce headline caution.
Q3 2028	1,064.24	-0.04%	+22.13%	Head-to-head competitive clinical disclosures and aggressive pharmacy benefit manager contracting talks generate tactical sentiment friction. Established physician loyalty cushions market share, limiting performance to narrow consolidation as investors weigh pricing sustainability.
Q4 2028	1,101.07	+3.46%	+26.36%	Relief following competitive data presentations and solid commercial execution in peripheral neuropathies restores buying momentum. Accelerating operating cash conversion and disciplined research expense management drive healthy quarterly valuation support into year-end.
Q1 2029	1,128.81	+2.52%	+29.54%	Full-year 2028 results confirm steady top-line compounding, while management demonstrates rigorous operational expense containment. Steady cash generation reinforces self-funding credentials, though valuation multiples face gradual downward pressure as organic percentage growth normalizes.
Q2 2029	1,163.24	+3.05%	+33.49%	Commercial launches across newly approved rheumatological indications unlock fresh volume streams, offsetting modest competitive pricing concessions. Subcutaneous convenience preserves high prescriber adherence, translating expanded patient onboarding into durable operating earnings growth.
Q3 2029	1,181.74	+1.59%	+35.61%	Routine annual payer formulary renegotiations and international pricing reference adjustments create mild gross-to-net drag. Resilient baseline prescription refills and expanding Asian market contributions cushion bottom-line earnings, enabling modest quarterly price advancement.
Q4 2029	1,220.97	+3.32%	+40.12%	Late-stage pipeline progression and maturing complement platform readouts reassure markets regarding long-term revenue durability. Healthier macroeconomic liquidity conditions provide modest multiple support, allowing accelerating net earnings to drive a solid quarterly advance.
Q1 2030	1,244.54	+1.93%	+42.82%	Annual 2029 financial disclosures highlight strong free cash flow conversion exceeding three billion dollars. Mature growth rates naturally moderate, prompting the valuation multiple to compress toward specialty pharmaceutical norms despite resilient cash generation.
Q2 2030	1,253.99	+0.76%	+43.91%	Next-generation pipeline candidates advance toward registrational milestones, partially dispelling long-term patent expiration anxieties. Competitor market entries in mature indications induce minor multiple compression, offset by steady cash accumulation on the balance sheet.
Q3 2030	1,284.84	+2.46%	+47.45%	Commercial execution across diversified indications maintains consistent cash flow generation, while high switching costs protect core neurology volume. Steady operational performance provides a reliable valuation floor, generating measured quarterly share price appreciation.
Q4 2030	1,317.86	+2.57%	+51.24%	Progress toward multi-indication corporate patient targets confirms operational maturity and robust recurring earnings. Sustained free cash flow accumulation sparks institutional speculation regarding potential shareholder capital returns, supporting positive equity performance into year-end.
Q1 2031	1,345.93	+2.13%	+54.46%	Full-year 2030 reporting illustrates elite biopharmaceutical operating margins near thirty-five percent. Exceptional cash conversion and pristine liquidity preserve defensive strength, though terminal multiple moderation limits quarterly price gains to underlying operational progress.
Q2 2031	1,370.29	+1.81%	+57.25%	Next-generation FcRn antibody development de-risks future franchise lifecycle transitions, mitigating biosimilar surveillance concerns. High recurring therapy demand and international market contributions sustain predictable cash flows, driving steady, low-volatility quarterly price appreciation.
Q3 2031	1,397.84	+2.01%	+60.41%	The five-year horizon concludes with the business firmly established as a profitable, cash-generative global immunology leader. Mature earnings compounding and defensive patent moats justify a solid valuation baseline, delivering dependable terminal equity compounding.

The investment thesis centers on a commercial biopharmaceutical powerhouse transitioning into self-funding cash generation. High switching costs in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy anchor durable prescription volumes at gross margins near 89%. Because commercial sales infrastructure is largely fixed, incremental label expansions into adjacent rheumatological conditions generate powerful operating leverage, driving operating margins toward 35%. However, the equity is not cheap; reconciling half-year filings reveals true trailing multiples near 40x rather than screened 27x figures. Long-term returns depend entirely on operational earnings compounding outpacing inevitable valuation multiple contraction.

Key insights

High patient switching barriers and subcutaneous autoinjector convenience protect core neurology revenues from immediate displacement by later-entering competitor molecules across outpatient clinics.
Fixed commercial sales infrastructure absorbs adjacent autoimmune indications with minimal marginal expense, enabling free cash flow to compound faster than top-line revenue.
Mandatory pharmacy benefit manager rebates and advancing rival FcRn inhibitors will compress terminal pricing, making volume expansion the primary earnings driver.

Deep Dive

Market consensus frames the company as European biotechnology's premier growth compounder, extrapolating 60% historical sales expansion and treating multi-indication approval across systemic autoimmunity as practically assured. Sell-side commentary heavily anchors on an unadjusted screening multiple near 27 times earnings, largely dismissing pipeline execution setbacks, looming pricing pressure from rival FcRn developers, and statutory rebate extractions by health insurance payers.

Paywalled preview begins: Deep Dive

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Alpha Gap & Repricing Catalysts

Where the published AI consensus diverged from the market narrative

Market narrative

Alpha gap

The crowd moderately underestimates value through an analytical misread of operating leverage, yet simultaneously overestimates near-term valuation cheapness due to screening data errors. While casual screens suggest a modest 27x trailing multiple on 7.6 billion dollars of revenue, reconstructed financial filings show true product revenue near 5.2 billion dollars, revealing a steeper 38x multiple. Crucially, the market fails to appreciate how fixed commercial infrastructure allows incremental indication revenues to convert into operating cash flows far faster than consensus anticipates.

Repricing catalyst

Pivotal registrational readouts for empasiprubart in multifocal motor neuropathy alongside commercial sales disclosures demonstrating operating margins exceeding 30% serve as the decisive convergence catalyst cluster. Demonstrating clinical efficacy in non-FcRn biology breaks single-molecule dependency narratives, while widening cash generation will force sell-side analysts to lift multi-year operating cash-flow estimates over the twelve-to-twenty-four-month monitoring window.

Published consensus context

Macro regime alignment

The macroeconomic setup is a mixed backdrop leaning slightly adverse for valuation multiples. A restrictive monetary policy environment with 5% sovereign bond yields exerts mechanical downward pressure on long-duration equity multiples. Conversely, inelastic clinical demand for life-altering autoimmune biologics and a fortress balance sheet holding over three billion dollars in net cash provide complete operational insulation from credit tightening.

Published consensus context

Advisor disagreement

The core debate centers on starting valuation and competitive duration. Optimistic views model uninterrupted multiple expansion above 30x forward earnings, assuming subcutaneous convenience and prescriber stickiness permanently insulate the franchise from competitor entry. Conversely, skeptical assessments argue that true trailing earnings multiples sit near 40x rather than screened 27x figures, warning that incoming FcRn rivals and statutory payer rebates will compress operating margins and multiples toward mature specialty pharmaceutical norms. Observable quarterly net realized pricing trends and comparative Phase 3 data from rival molecules throughout 2027 will resolve this valuation divide.

Published scenario analysis

Base-case forces, risks, and opportunities

Top drivers and tailwinds

Multi-indication autoimmune franchise label expansion: Systematic clinical label expansion of efgartigimod beyond generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy into rheumatology targets over 50,000 global patients. Because manufacturing batches and clinical foundations are already established, each incremental approval delivers high-margin volume that widens operating leverage, expanding long-term earning power across the five-year horizon. Expected impact: +34%.
Commercial operating leverage cash conversion: Elite gross margins near 89% combine with an established global sales organization to drive rapid operational leverage. Having crossed structural profitability, selling expenses scale sub-linearly with new indication rollouts. This dynamic widens operating margins toward 35%, converting top-line commercial growth into accelerating free cash flow that compounds per-share intrinsic business value. Expected impact: +24%.
Subcutaneous convenience locks prescriber switching: Widespread adoption of subcutaneous Vyvgart Hytrulo and prefilled autoinjectors displaces burdensome hospital infusions, achieving patient adherence above 85%. Once chronic neurological patients achieve clinical disease stability at home, neurologists face steep behavioural switching barriers against altering regimens. This entrenched prescriber loyalty protects core market share and insulates commercial volume from early competitor incursions. Expected impact: +20%.
Debt-free fortress balance sheet self-funding: Operating with virtually zero debt and substantial liquid reserves shields the business from credit contractions and elevated benchmark interest rates. Strong internal operating cash flows fully self-fund ten parallel registrational clinical trials and selective bolt-on acquisitions without equity dilution, preserving per-share capital compounding while competitors face capital-market financing constraints. Expected impact: +14%.

Top frictions and headwinds

Rival FcRn class competitive encroachment: Emerging neonatal Fc receptor antagonists from well-funded multinational pharmaceutical competitors contest core neurology indications. Although first-mover physician loyalty provides a strong defense, incoming alternatives force elevated promotional spending and aggressive hospital formulary rebating. This competitive crowding caps terminal net realized pricing per patient, tempering prospective operating margin expansion across outer forecast years. Expected impact: -16%.
Macroeconomic duration multiple compression drag: A higher-for-longer monetary regime featuring elevated sovereign bond yields imposes mechanical downward pressure on high-multiple growth equities. Trading at roughly 38-40 times normalized earnings, the equity faces inevitable multiple compression as discount rates penalize outer-year terminal cash flows. This duration tax absorbs a meaningful portion of underlying operational earnings growth over the horizon. Expected impact: -15%.
Payer utilization restrictions and statutory rebates: Intensifying healthcare budget scrutiny across the United States and Europe generates persistent downward pressure on specialty biologic reimbursements. Commercial insurers increasingly enforce step therapy, prior authorizations, and higher gross-to-net statutory rebates before approving chronic therapy. This administrative friction lengthens patient onboarding cycles, forcing unit volume to shoulder the entire top-line expansion burden. Expected impact: -13%.
Heavy registrational clinical research expenditure: Simultaneously advancing ten clinical-stage registrational programs across multiple rare diseases consumes over 1.5 billion dollars in annual research expenditures. High patient recruitment costs in rare cohorts, trial complexity, and ongoing post-acquisition integration outlays absorb substantial gross profit. This persistent reinvestment burden constrains near-term free cash flow yield expansion, deferring peak operating margin realization. Expected impact: -10%.

Tail risks

Pivotal registrational clinical trial endpoint failure: A high-profile Phase 3 trial failure in an advanced pipeline indication, such as autoimmune myositis or multifocal motor neuropathy, would severely impair market confidence. Triggered by an inability to achieve statistical significance versus placebo, this setback would invalidate multi-franchise expansion assumptions, prompting immediate earnings write-downs, pipeline restructuring, and sharp equity multiple derating. Probability: +30%. Expected impact: -28%.
Severe postmarketing chronic infection safety signal: Commercial real-world pharmacovigilance identifying severe opportunistic infection clusters or paradoxical immune toxicities from prolonged systemic IgG clearance could trigger FDA black-box warnings or restrictive patient monitoring requirements. This regulatory intervention would paralyze new patient onboarding, accelerate prescriber hesitation, and trigger sharp downgrades to peak penetration across chronic neurological and rheumatological indications. Probability: +16%. Expected impact: -38%.

Tail opportunities

Empasiprubart pivotal breakthrough in motor neuropathy: Topline Phase 3 registrational success for empasiprubart in multifocal motor neuropathy would validate a second proprietary biologic platform targeting C2 complement inhibition. Triggered by statistically superior functional stabilization data, this breakthrough would establish an independent multi-billion-dollar rare disease franchise, dispelling single-molecule concentration concerns and prompting institutional analysts to aggressively raise long-term terminal valuation multiples. Probability: +38%. Expected impact: +28%.
Blockbuster registrational victory in Sjogrens syndrome: Positive pivotal Phase 3 registrational readouts for efgartigimod in primary Sjögren's syndrome would unlock a prevalent rheumatological population exceeding 300,000 addressable patients currently lacking approved targeted biologic therapies. This clinical triumph would expand peak addressable market potential by over four billion dollars annually, triggering substantial consensus earnings upgrades and accelerating enterprise free cash flow compounding. Probability: +32%. Expected impact: +32%.

What to monitor

Thesis watchpoints

-- Quarterly global net product sales exceeding 1.6 billion dollars while sustaining gross margins above 88% through 2027 confirms commercial operating leverage.

Key insights

US net price per patient declining over 10% or rival FcRn entrants capturing more than 15% new patient share signals competitive erosion.
Failure of empasiprubart in Phase 3 motor neuropathy trials or regulatory rejection in rheumatology requires immediate multi-asset growth thesis revision.

Company Financial Analysis

Argen-X Earnings and Financials Analysis by AI

Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.

Earnings and financials

AI Review

The company has completed a historic turnaround, transitioning from heavy development-stage cash losses into substantial commercial profitability. Product revenue surged 84.7% in fiscal 2025 to 4.15 billion dollars, driven by rapid patient adoption of Vyvgart in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. Reconstructed financial filings indicate true trailing product sales near 5.2 billion dollars through mid-2026. This explosive trajectory reflects genuine operating leverage rather than transient accounting windfalls. As recurring prescription volumes expand across specialized neurology clinics, operating income and cash flows have turned decisively positive. Patient demand for life-altering therapies remains highly predictable, providing a dependable foundation for long-term cash generation.

Revenue, earnings, and cash flow

The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.

Revenue, net income, and free cash flow history
Fiscal year	Revenue	Net income	Free cash flow
2025	USD 4.2B	USD 1.3B	USD 876M
2024	USD 2.2B	USD 833M	USD -84.5M
2023	USD 1.2B	USD -295.1M	USD -464.1M
2022	USD 410.7M	USD -709.6M	USD -966.6M
2021	USD 528.3M	USD -408.3M	USD -728.2M

Valuation context: historical P/E

The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.

Historical price-to-earnings ratios
Fiscal year	P/E	Earnings basis	Currency basis	Ticker / reporting
2025	33.8x	TTM	USD-normalized	EUR / USD
2024	55.1x	TTM	USD-normalized	EUR / USD
2023	--	TTM	Loss-making	EUR / USD
2022	--	Annual	Loss-making	EUR / USD
2021	--	Annual	Loss-making	EUR / USD

P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.

Profitability and margins

AI Review

Profitability trends highlight the remarkable economic power of proprietary biologic therapies. Gross margins remained stellar at 89.1% in fiscal 2025, reflecting exceptional pricing power and low incremental manufacturing costs per dose. Operating margins swung dramatically from negative territory in 2024 to 24.8% in 2025, climbing above 30% in mid-2026. This structural margin explosion stems from classic operating leverage. Because marketing and medical affairs teams cover concentrated specialist networks, sales overhead grows much slower than overall revenue. As new indications utilize the same sales infrastructure, incremental revenue drops straight to the bottom line, establishing a durable high-margin profile.

The table compares up to five fiscal years of operating income and reported profitability margins.

Operating income and margin history
Fiscal year	Operating income	Operating margin	Net margin
2025	USD 1B	24.8%	32.4%
2024	USD -21.7M	-1.0%	37.1%
2023	USD -425M	-34.7%	-24.1%
2022	USD -720.3M	-175.4%	-172.8%
2021	USD -348.7M	-66.0%	-77.3%

Balance sheet and leverage

AI Review

The balance sheet is designed as an impenetrable financial fortress, providing complete operational autonomy during volatile economic environments. Total assets stood at 8.68 billion dollars against 7.32 billion dollars in shareholder equity at year-end 2025. With a debt-to-equity ratio of just 0.01 and a current ratio exceeding 5.2, the company carries virtually no financial debt. This pristine solvency profile fully insulates operations from high central bank interest rates and credit market contractions. Even after committing 2.2 billion dollars in cash to acquire Forte Biosciences post-period, remaining liquidity comfortably funds late-stage clinical trials internally, eliminating the need for dilutive equity offerings or costly debt issuance.

The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.

Balance sheet leverage and liquidity history
Fiscal year	Total debt	Cash + short-term investments	Net cash / (debt)	Current ratio
2025	USD 47.2M	USD 4.4B	USD 3.4B net cash	5.23x
2024	USD 37.7M	USD 3.4B	USD 1.5B net cash	7.29x
2023	USD 20M	USD 3.2B	USD 2B net cash	9.75x
2022	USD 12.4M	USD 2.2B	USD 788.3M net cash	9.18x
2021	USD 11.5M	USD 2.3B	USD 1.3B net cash	8.44x

Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.

Capex and investment intensity

AI Review

Management maintains an exceptionally capital-light operating structure, spending almost nothing on physical property, factories, or heavy machinery. In fiscal 2025, physical capital expenditure accounted for a negligible 0.15% of total revenue. Instead of building expensive manufacturing facilities, the company outsources biologic production to specialized contract development partners like Fujifilm. This disciplined strategy frees up operational cash to be reinvested straight into intellectual property and clinical trials. Research spending reached 1.42 billion dollars in 2025 to advance ten parallel registrational programs. While this clinical intensity absorbs substantial near-term cash, it maximizes return on invested capital by avoiding factory depreciation and fixed plant obsolescence.

The table compares up to five fiscal years of capital expenditure and research-and-development investment.

Capital expenditure and research and development history
Fiscal year	Capital expenditure	R&D spend
2025	USD 6.4M	USD 1.4B
2024	USD 1.7M	USD 949.3M
2023	USD 43.8M	USD 859.5M
2022	USD 103.8M	USD 663.4M
2021	USD 121.4M	USD 580.5M

Immutable published data

Averaged consensus horizons

The table preserves this publication's original rating, return, and advisor-agreement measurements by forecast horizon.

Horizon	Rating	Score incl. dividends	Compounded return incl. dividends	Direction agreement	Snapshot
1Y	BUY	185	+14.8%	Not available	ORIGINAL
5Y	BUY	141	+76.6%	Not available	ORIGINAL

Averaged consensus scenarios

The table outlines the frozen bear, consensus, and bull price scenarios for each published forecast period.

Period	Date	Bear case	Consensus	Bull case	AI Advisors
+3M	December 18, 2026	836.54	906.88	949.83	14
+6M	March 18, 2027	870.01	941.34	1,016.31	14
+9M	June 18, 2027	896.11	972.44	1,077.29	14
+1Y	September 18, 2027	914.49	1,000.35	1,131.16	14
+15M	December 18, 2027	877.91	1,042.81	1,221.65	14
+18M	March 18, 2028	860.36	1,067.28	1,294.95	14
+21M	June 18, 2028	886.17	1,099.54	1,346.75	14
+2Y	September 18, 2028	841.86	1,119.15	1,441.02	14
+27M	December 18, 2028	816.6	1,162.07	1,556.3	14
+30M	March 18, 2029	800.27	1,195.84	1,649.68	14
+33M	June 18, 2029	816.28	1,234.37	1,732.16	14
+3Y	September 18, 2029	783.63	1,258.19	1,801.45	14
+39M	December 18, 2029	767.95	1,305.59	1,927.55	14
+42M	March 18, 2030	775.63	1,333.51	2,043.2	14
+45M	June 18, 2030	752.36	1,360.55	2,145.36	14
+4Y	September 18, 2030	759.89	1,394.97	2,231.18	14
+51M	December 18, 2030	744.69	1,438.24	2,365.05	14
+54M	March 18, 2031	759.58	1,473.35	2,483.3	14
+57M	June 18, 2031	751.99	1,504.24	2,582.63	14
+5Y	September 18, 2031	759.51	1,538.89	2,685.94	14

Frozen comparison context

SPDR S&P 500 ETF Trust forecast context

The benchmark definition and forecast path are frozen with this publication so future benchmark changes do not rewrite the historical comparison.

Benchmark snapshot: 761.69 on September 18, 2026

Period	Date	Bear case	Consensus	Bull case
+3M	December 18, 2026	723.6055	750.2647	769.3069
+6M	March 18, 2027	701.8973	736.44	784.693
+9M	June 18, 2027	695.1	743.3975	808.2338
+1Y	September 18, 2027	681.198	755.1476	816.3162
+15M	December 18, 2027	688.01	776.2182	840.8057
+18M	March 18, 2028	701.7702	787.1259	857.6218
+21M	June 18, 2028	722.8233	802.8344	883.3504
+2Y	September 18, 2028	730.0515	812.0465	892.1839
+27M	December 18, 2028	751.9531	839.1839	927.8713
+30M	March 18, 2029	766.9921	850.5008	946.4287
+33M	June 18, 2029	782.332	872.3935	965.3573
+3Y	September 18, 2029	790.1553	885.5111	975.0109
+39M	December 18, 2029	805.9584	909.5618	1,004.2612
+42M	March 18, 2030	822.0776	916.132	1,024.3464
+45M	June 18, 2030	830.2984	936.5109	1,055.0768
+4Y	September 18, 2030	830.2984	947.3438	1,065.6276
+51M	December 18, 2030	855.2073	969.5876	1,097.5964
+54M	March 18, 2031	872.3114	979.9863	1,119.5483
+57M	June 18, 2031	889.7577	999.6043	1,141.9393
+5Y	September 18, 2031	898.6553	1,011.7644	1,153.3587

Frozen comparison context

EURUSD.FOREX forecast context

The batch's original direct_listing_to_usd path is preserved for transparent interpretation of USD-normalized returns.

FX snapshot: 1.15 on September 18, 2026

Period	Date	Bear case	Consensus	Bull case
+3M	December 18, 2026	1.127	1.136	1.1385
+6M	March 18, 2027	1.1045	1.1255	1.1385
+9M	June 18, 2027	1.0934	1.1272	1.1499
+1Y	September 18, 2027	1.0934	1.1312	1.1614
+15M	December 18, 2027	1.1044	1.1401	1.173
+18M	March 18, 2028	1.0824	1.1452	1.1847
+21M	June 18, 2028	1.0715	1.151	1.1966
+2Y	September 18, 2028	1.0823	1.1584	1.2085
+27M	December 18, 2028	1.0931	1.1617	1.2085
+30M	March 18, 2029	1.0822	1.1694	1.2206
+33M	June 18, 2029	1.0713	1.1719	1.2328
+3Y	September 18, 2029	1.0713	1.1763	1.2328
+39M	December 18, 2029	1.0713	1.1781	1.2452
+42M	March 18, 2030	1.082	1.1832	1.2452
+45M	June 18, 2030	1.0712	1.1867	1.2576
+4Y	September 18, 2030	1.0605	1.1894	1.2699
+51M	December 18, 2030	1.0605	1.1887	1.2826
+54M	March 18, 2031	1.0711	1.1913	1.2826
+57M	June 18, 2031	1.0818	1.1971	1.2826
+5Y	September 18, 2031	1.0818	1.1964	1.2955

Behind the synthesis

How each opinion shapes the consensus

14 opinions · 100% allocated

Across the submitted evaluations, an independently supported pattern confirms that commercial execution in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy generates substantial operating leverage over an established sales chassis. However, several reports uncritically propagate a flawed screening dataset claiming 7.6 billion dollars in trailing revenue and a 26.7x multiple, which incorrectly aggregates half-year cumulative totals. Primary SEC and corporate filings reveal true trailing product revenues near 5.2 billion dollars, placing the actual earnings multiple closer to 38x. The strongest contrarian case emphasizes that second-generation competitors and mandatory payer rebates will erode realized pricing just as higher benchmark yields depress growth multiples. Evaluations that forensically corrected the financial baseline and accounted for post-balance-sheet cash deployment, such as the Forte Biosciences acquisition, receive the highest weights. Overly euphoric trajectories assuming perpetual multiple expansion amid encroaching class competition are heavily downweighted to ensure realistic risk-adjusted synthesis.

AI RESEARCHER

Universal Investor AI

The Polymath

Opus 5

Weight16.0/100

This rigorous evaluation stands out by forensically reconciling financial filings, debunking inflated screening database revenues, and identifying true valuation multiples near 40x. Its causal modeling soundly integrates Section 232 tariff considerations, duration drag, and competitive head-to-head friction, providing superior evidence-based discipline that justifies high relative weighting.

AI RESEARCHER

Universal Investor AI

The Polymath

GPT-6 Astra

Weight16.0/100

This perspective provides exceptional analytical rigor by directly adjusting for the $2.2 billion Forte Biosciences acquisition and reconciling actual TTM product revenues to roughly $5.2 billion. Its disciplined recognition that multiple contraction will offset part of operational growth delivers superior causal consistency, warranting top weighting.

AI THINKER

Superintelligence AI

The Anthropologist

Gemini 3.8 Flash

Weight9.0/100

This report accurately recognizes that price-to-sales multiples face inevitable contraction from 8.5x toward 5.5x as the core franchise matures. Its realistic recognition of payer pushback and commercial step-therapy tempers top-line optimism, though it still relies on unadjusted trailing revenue datasets, earning a moderate weight.

AI RESEARCHER

Michael Burry AI

The Vulture

Gemini 3.8 Flash

Weight9.0/100

This contrarian perspective provides a vital counterweight by rigorously modeling competitive erosion from next-generation FcRn entrants and aggressive pharmacy benefit manager rebate extraction. Even though its terminal volume stagnation is overly severe, its multiple contraction logic provides essential risk discipline, earning meaningful weight.

AI RESEARCHER

Ray Dalio AI

The Strategist

Gemini 3.8 Flash

Weight8.0/100

The evaluation correctly identifies all-weather operational insulation and non-discretionary autoimmune treatment demand amid restrictive monetary policy. Its analysis balances top-line growth with multiple compression risks. Nevertheless, reliance on aggregated database revenue metrics without reconciling half-year filing figures slightly impairs its causal foundation, justifying a controlled weight.

AI RESEARCHER

Sherlock Holmes AI

The Whistleblower

Gemini 3.8 Flash

Weight8.0/100

This report delivers detailed operational analysis of neuromuscular prescribers, supply-chain commitments, and outsourced manufacturing dynamics. While it relies on unadjusted screening datasets, its careful treatment of partner royalties, manufacturing obligations, and commercial reimbursement hurdles provides grounded qualitative evidence, warranting a solid weight.

AI RESEARCHER

Elon Musk AI

The Visionary

Gemini 3.8 Flash

Weight6.0/100

This assessment grounds switching costs in patient convenience and first-principles biological mechanics. However, it incorporates unadjusted trailing revenue data and understates the friction of payer step-therapy and statutory price concessions, justifying a moderate, well-calibrated weighting.

AI RESEARCHER

Warren Buffett AI

The Value Seeker

Gemini 3.8 Flash

Weight5.0/100

This perspective articulates valid switching costs in chronic neuromuscular care and capital-light biologic manufacturing. However, it relies on unadjusted screened sales metrics, uncritically accepts headline cash figures without deducting post-period commitments, and overstates terminal multiple resilience in a high-rate regime, warranting a modest weighting.

AI RESEARCHER

Niccolo Machiavelli AI

The Insider

Gemini 3.8 Flash

Weight5.0/100

This analysis provides useful insights into orphan drug exclusivity perimeters and switching costs for subcutaneously treated patients. However, it assumes an aggressive 26x terminal forward multiple and overstates mid-term operating cash flow conversion while repeating unadjusted screening database numbers, warranting a tempered allocation.

AI RESEARCHER

Superintelligence AI

The Anthropologist

Gemini 3.8 Flash

Weight5.0/100

The report offers sound qualitative commentary regarding sub-linear commercial cost scaling across adjacent neurological and rheumatological indications. However, it relies heavily on unverified database metrics, neglects post-period cash outlays for pipeline acquisitions, and adopts an optimistic stance toward multiple stability, justifying a reduced weight.

AI THINKER

Universal Investor AI

The Polymath

Gemini 3.8 Flash

Weight4.0/100

While effectively framing commercial operating leverage and prescriber stickiness, this report accepts screened financial metrics without reconciling underlying half-year SEC filings. Its expectation of forward multiple expansion to 32x normalized earnings conflicts with tighter monetary conditions and competitive class entry, necessitating a lower weight.

AI RESEARCHER

Universal Investor AI

The Polymath

Gemini 3.8 Flash

Weight4.0/100

The analysis provides credible mechanics on autoinjector patient persistence and second-generation pipeline development. However, it models aggressive earnings compounding while repeating distorted trailing twelve-month revenue data and projecting multiple expansion that understates prospective pricing resistance, justifying a conservative weight.

AI THINKER

Warren Buffett AI

The Value Seeker

Gemini 3.8 Flash

Weight3.0/100

Although capturing the commercial power of 89% gross margins, this report exhibits extreme optimism by projecting 104% returns. It relies on distorted screening figures and assumes sustained high multiples despite emerging class rivals and tightening reimbursement, requiring a heavy discount for uncritical assumptions.

AI RESEARCHER

J.P. Morgan AI

The Titan

Gemini 3.8 Flash

Weight2.0/100

This report presents an overly promotional narrative projecting a tripling of equity value and $16.5 billion in revenue. It ignores multiple compression arithmetic, downplays competitor launches, and relies on distorted screened financials, warranting the lowest assigned weight due to poor analytical realism.

Skip to references

Research Provenance

References & Context

This Argen-X consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.

Primary analysis inputs

iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.

Independent AI Advisor panel

AI Advisors: 14
AI Researchers: 11
AI Thinkers: 3

Sources retained from AI Researcher searches

Asset-specific · Researcher web

Showing the top 15 of 73 deduplicated sources retained for this batch.

01ARGENX SE - Form CORRESP - FY2025sec.gov
02Argenx stock holds near recent highs as Jefferies sticks to Buy ratingad-hoc-news.de
03argenx | argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositisargenx.com
04argenx | argenx Completes Acquisition of Forte Biosciences, Inc.argenx.com
05argenx | argenx Highlights 2026 Strategic Prioritiesargenx.com
06argenx | argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Updateargenx.com
07argenx | argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Updateargenx.com
08argenx | argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Updateargenx.com
09argenx | argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipelineargenx.com
10Trump Administration Announces Section 232 Tariffs on Pharmaceuticals | Brownsteinbhfs.com
11U.S. Pharma Tariffs And MFN Become Law After April 2 Updateclinicalleader.com
12Check out argenx SE's stock price (ARGX) in real timecnbc.com
13ARGX Stock Quote Price and Forecast | CNNcnn.com
14FcRn Inhibitor Drug Market Size, Trends, Growth Report 2033databridgemarketresearch.com
15A New Round in US Pharma Tariffs: What's at Play? - DCAT Value Chain Insightsdcatvci.org

And 58 more sources were used and retained in the batch inventory.

Context retained with this Consensus

The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.

Global context snapshot

2025 Full-Year Global Market and World-Events Context

Download Archived Snapshot

Coverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31

This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.

The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.

Top 3 market shifts from 2025 Full-Year Global Market and World-Events Context
Top 3 Market Shifts From File	Date	Status
DeepSeek shock and AI economics reset	2025-01-27	OPEN ENDED TREND
US tariff regime escalation and trade-system rupture	2025-02-01	ACTIVE POLICY REGIME
Federal Reserve easing cycle after a prolonged hold	2025-09-17	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics US Bureau of Economic Analysis US Treasury US Energy Information Administration Reuters World Associated Press World News BBC World

And more sources from the retained context package.

2026 Year-to-Date Global Market and World-Events Context Through September 20

Download Archived Snapshot

Coverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20

January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.

Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.

Top 3 market shifts from 2026 Year-to-Date Global Market and World-Events Context Through September 20
Top 3 Market Shifts From File	Date	Status
Renewed monetary tightening amid persistent inflation	2026-01-30	ACTIVE POLICY REGIME
Iran/Hormuz conflict and wider energy-security disruption	2026-02-28	ONGOING
Tariff legal reset and strategic supply restrictions	2026-02-20	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics European Central Bank International Monetary Fund Reuters World Associated Press World News

And more sources from the retained context package.

Fundamental context

Income statement

9 fields

depreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields

Balance sheet

11 fields

cash · commonStockSharesOutstanding · netDebt · netReceivables · +7 more fields

Cash flow

4 fields

capitalExpenditures · freeCashFlow · salePurchaseOfStock · totalCashFromOperatingActivities

annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-09-30–2026-06-30, 12 periods

Currencies cited: EUR, USD (quote EUR; primary reporting USD; converted/valuation USD).

End of the paywalled preview

The excerpt from Deep Dive to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Individual AI Advisor reports
- Separate investment theses, scenarios, factors, risks and opportunities
- Quarterly forecast events and supporting citations
- Published advisor configuration snapshots
Interactive research tools
- Zoomable forecast and benchmark comparisons
- Currency and dividend assumptions
- Additional datasets and eligible historical research

Explore complete public research examples

These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.